Compugen announced publication of an abstract on preliminary data showing anti-tumor activity and potent immune modulation with the combination of COM701 and nivolumab in metastatic MSS-CRC patients. Adding COM701 to nivolumab resulted in a response rate of 9% in 22 MSS-CRC patients with two partial responses occurring in 17 patients with liver metastases. While the numbers of patients were small, the data warrant further evaluation. Encouraging preliminary antitumor activity in the subset of MSS-CRC patients with liver metastases, ORR 2/17 – 12% -, compared to 0% ORR historically for other immunotherapies in a U.S. patient population. Further clinical investigation of COM701 and anti-PD-1, triple combination with COM902 in MSS-CRC patients.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CGEN: